Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
Volume 0.45M
Average 0.26M
PBYI Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Puma Biotechnology, Inc.NASDAQ: PBYI
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $1.9M fell 6.4% year over year, ahead of the -13.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 17.3% from the prior quarter. Over 3 fiscal years it compounded at -16.3% a year.
Context
- Stock-based compensation amounted to 3.0% of revenue in FY2025, down 0.5 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -6.4% holds above the trailing-twelve-month pace of -13.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.94M USD
- Year-over-year change
- -15.8%
- 4-year CAGR
- -32.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.94M | -15.8% |
| FY2024 | 2024-12-31 | 8.25M | -19.5% |
| FY2023 | 2023-12-31 | 10.25M | -13.4% |
| FY2022 | 2022-12-31 | 11.83M | -63.8% |
| FY2021 | 2021-12-31 | 32.63M | — |
Stock-Based Compensation vs competitors
How PBYI compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -13.7% is the 8th highest of 11, against a peer median of +23.0%.
- Stock-based compensation amounts to 3.0% of revenue for PBYI, versus a peer median of 15.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $58.58M USD | +109.9% | +22.9% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥26.02M CNY | +1.1% | -74.4% | — |
| LTM Mar 2026 | $25.38M USD | +66.4% | — | — | |
| LTM Jun 2026 | $19.89M USD | -153.0% | +30.1% | 11.7% | |
| LTM Mar 2026 | $15.73M USD | +224.1% | +209.1% | — | |
| LTM Mar 2026 | $12.55M USD | -55.6% | -11.3% | 8.0% | |
| LTM Mar 2026 | $9.66M USD | +26.4% | +15.9% | 19.5% | |
| LTM Mar 2026 | $6.81M USD | -13.7% | -16.3% | 3.0% | |
| LTM Mar 2026 | CA$6.75M CAD | +101.1% | +21.4% | — | |
| LTM Mar 2026 | $6.38M USD | -39.9% | -18.4% | — | |
| LTM Mar 2026 | $5.99M USD | +19.7% | +10.2% | 1140.6% | |
| Peer median (excluding PBYI) | — | +23.0% | +15.9% | 15.6% | |
Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (29.13M) | 2K | 21.59M | 30.28M | 31.11M |
| Depreciation & Amortization | 11.31M | 9.84M | 11.52M | 11.52M | 10.94M |
| Deferred Income Tax | 0 | 0 | 0 | (7.08M) | 3.25M |
| Stock-Based Compensation | 32.63M | 11.83M | 10.25M | 8.25M | 6.94M |
| Change in Working Capital | (1.31M) | (44.5M) | (17.85M) | (3.54M) | (10.08M) |
| Accounts Receivables | (5.98M) | (7.82M) | (8.37M) | 16.35M | (21.28M) |
| Inventory | (3.66M) | 2.58M | (2.55M) | (1.64M) | 3.21M |
| Accounts Payables | (902K) | (4.73M) | 449K | (1.38M) | (453K) |
| Other Working Capital | 9.23M | (34.52M) | (7.38M) | (16.86M) | 8.45M |
| Other Non-Cash Items | 7.15M | 7M | 1.51M | (519K) | (358K) |
| Operating Cash Flow | 20.65M | (15.83M) | 27.01M | 38.92M | 41.8M |
| Capital Expenditures | 0 | (7M) | (12.64M) | (56K) | (71K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (38.07M) | (4.84M) | (23.81M) | (76.23M) | (108.14M) |
| Sales of Investments | 27.19M | 18.94M | 17.33M | 55.85M | 72.02M |
| Other Investing Activities | 0 | 0 | (12.5M) | 0 | 0 |
| Investing Cash Flow | (10.88M) | 7.1M | (19.13M) | (20.44M) | (36.19M) |
| Debt Repayment | (1.5M) | 0 | 0 | (33.33M) | (44.44M) |
| Common Stock Issued | 0 | 12.5M | 0 | 150K | 130K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (30.43M) | (277K) | 0 | (666K) | (888K) |
| Financing Cash Flow | (31.93M) | 12.22M | 0 | (33.85M) | (45.2M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (22.16M) | 3.5M | 7.88M | (15.37M) | (39.58M) |
| Free Cash Flow | 20.65M | (22.83M) | 14.37M | 38.86M | 41.73M |
Puma Biotechnology, Inc.
NASDAQ:PBYI
Intrinsic Alpha fair value
Locked
Current Price
$7.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.